Spe C Stock Analysis Special Opportunities Fund C Preferred Holds Flat At 100 Mark 20260403 VNO Q1 2026 Earnings EPS Misses Estimates as Office Sector Pressures Persist STSS Q3 2025 Earnings Losses Widen Sharply as Revenue Remains Absent Dianthus Therapeutics Q1 2026 Earnings EPS Beat Amid PreRevenue Stage Novo Nordisk AS NVO Q1 2026 Earnings Strong EPS Beat Driven by Obesity and Diabetes Portfolio ISBA Q1 2026 Earnings Significant EPS Miss Despite Modest Stock Gain